The Optimizing Lung Screening Trial (WF-20817CD): Multicenter Randomized Effectiveness Implementation Trial to Increase Tobacco Use Cessation for Individuals Undergoing Lung Screening
Kristie L Foley, Emily V Dressler, Kathryn E Weaver, Erin L Sutfin, David P Miller Jr, Christina Bellinger, Carol Kittel, Rebecca J Stone, W Jeffrey Petty, Stephanie R Land, John Spangler, Glenn J Lesser, Caroline Chiles, Optimizing Lung Screening Trial Writing Team, Kristie L Foley, Emily V Dressler, Kathryn E Weaver, Erin L Sutfin, David P Miller Jr, Christina Bellinger, Carol Kittel, Rebecca J Stone, W Jeffrey Petty, Stephanie R Land, John Spangler, Glenn J Lesser, Caroline Chiles, Optimizing Lung Screening Trial Writing Team
Abstract
Background: Half of all people who undergo lung cancer screening (LCS) are current tobacco users. However, few published studies have explored how to implement effective tobacco use treatment optimally during the LCS encounter.
Research question: Was the Optimizing Lung Screening intervention (OaSiS) effective at reducing tobacco use among patients undergoing LCS in community-based radiology facilities?
Study design and methods: The OaSiS study (Identifier: WF-20817CD) is an effectiveness-implementation hybrid type II cluster randomized trial of radiology facilities conducted in partnership with the Wake Forest National Cancer Institute Community Oncology Research Program research base. We randomly assigned 26 radiology facilities in 20 states to the intervention or usual care group. Staff at intervention facilities implemented a variety of strategies targeting the clinic and care team. Eligible patient participants were 55 to 77 years of age undergoing LCS and currently using tobacco. Of 1,094 who completed a baseline survey (523 intervention group, 471 control group) immediately before the LCS appointment, 956 completed the 6-month follow-up (86% retention rate). Fifty-four percent of those who reported not using tobacco at 6 months completed biochemical verification via mailed cotinine assay. Generalized estimating equation marginal models were used in an intention-to-treat analysis to predict 7-day tobacco use abstinence.
Results: The average self-reported abstinence among participants varied considerably across facilities (0%-27%). Despite a significant increase in average cessation rate over time (0% at baseline to approximately 13% at 6 months; P < .0001), tobacco use did not differ by trial group at 14 days (OR, 0.96; 95% CI, 0.46-1.99; P = .90), 3 months (OR, 1.17; 95% CI, 0.69-1.99; P = .56), or 6 months (OR, 0.97; 95% CI, 0.65-1.43; P = .87).
Interpretation: The OaSiS trial participants showed a significant reduction in tobacco use over time, but no difference by trial arm was found.
Trial registry: ClinicalTrials.gov; No.: NCT03291587; URL: www.
Clinicaltrials: gov.
Keywords: NCORP; cessation; implementation; lung screening; smoking.
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Source: PubMed